Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

Mar 16, 2022 8:00am EDT

Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference

Mar 10, 2022 7:00am EST

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery

Mar 08, 2022 8:00am EST

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

Mar 07, 2022 8:00am EST

Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®

Mar 02, 2022 7:00am EST

Baudax Bio Announces Pricing of $10.0 Million Public Offering

Feb 24, 2022 11:23pm EST

Baudax Bio Announces Proposed Public Offering of Securities

Feb 24, 2022 4:40pm EST

Baudax Bio Announces 1-for-35 Reverse Stock Split

Feb 15, 2022 8:29pm EST

Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Jan 04, 2022 7:00am EST

Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2021 4:05pm EST